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Abstract
Introduction: The underlying pathogenic mechanism of a large fraction of DNA variants of disease-causing genes
is the disruption of the splicing process. We aimed to investigate the effect on splicing of the BRCA2 variants
c.8488-1G > A (exon 20) and c.9026_9030del (exon 23), as well as 41 BRCA2 variants reported in the Breast Cancer
Information Core (BIC) mutation database.
Methods: DNA variants were analyzed with the splicing prediction programs NNSPLICE and Human Splicing
Finder. Functional analyses of candidate variants were performed by lymphocyte RT-PCR and/or hybrid minigene
assays. Forty-one BIC variants of exons 19, 20, 23 and 24 were bioinformatically selected and generated by PCR-
mutagenesis of the wild type minigenes.
Results: Lymphocyte RT-PCR of c.8488-1G > A showed intron 19 retention and a 12-nucleotide deletion in exon
20, whereas c.9026_9030del did not show any splicing anomaly. Minigene analysis of c.8488-1G > A displayed the
aforementioned aberrant isoforms but also exon 20 skipping. We further evaluated the splicing outcomes of 41
variants of four BRCA2 exons by minigene analysis. Eighteen variants presented splicing aberrations. Most variants
(78.9%) disrupted the natural splice sites, whereas four altered putative enhancers/silencers and had a weak effect.
Fluorescent RT-PCR of minigenes accurately detected 14 RNA isoforms generated by cryptic site usage, exon
skipping and intron retention events. Fourteen variants showed total splicing disruptions and were predicted to
truncate or eliminate essential domains of BRCA2.
Conclusions: A relevant proportion of BRCA2 variants are correlated with splicing disruptions, indicating that RNA
analysis is a valuable tool to assess the pathogenicity of a particular DNA change. The minigene system is a
straightforward and robust approach to detect variants with an impact on splicing and contributes to a better
knowledge of this gene expression step.
Introduction
Germline mutations in the BRCA1 (MIM# 113705) and
BRCA2 (MIM# 600185) genes confer a high lifetime risk
of developing breast/ovarian cancer [1] and account for
about 16% of the breast cancer familial risk [2]. Nearly
3,500 different DNA variants of BRCA1 and BRCA2
have been reported at the Breast Cancer Information
Core Database (BIC) [3]. Only truncating mutations
(1,457 nonsense and frameshift variants, 41.6%), variants
in natural splice sites (141, 4%) and a minor fraction of
the 1,346 BIC missense variants have been catalogued as
deleterious [4,5]. Little is known about the pathogenicity
of most of the remaining variants (approximately 50%),
usually referred to as unclassified variants (UV), which
complicates genetic counseling in UV carrier families
[6]. A more reliable interpretation and classification of
these sequence changes will improve the clinical man-
agement of cancer patients and their families. Several
methods have been developed to classify them, including
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functional assays [7] and integrated statistical analysis of
several parameters [8,9].
Genetic variants in disease-responsible genes that dis-
rupt the splicing code have a key role in human hereditary
disorders [10,11]. In fact, it has been estimated that more
than 60% of sequence variations may affect pre-mRNA
processing [12]. Therefore, splicing disruptions should be
considered a core mechanism of gene inactivation to be
investigated in UVs. Splicing mutations are traditionally
considered those that affect essential nucleotides of the
donor (GT) and the acceptor (AG) sites [13], although
other intronic and exonic nucleotides are critical for splice
site selection [14]. Furthermore, exon recognition is sup-
ported by other essential cis-regulatory motifs, the
so-called splicing enhancers (ESE, ISE) or silencers (ISE,
ISS) that are usually bound by SR and hnRNP proteins,
respectively. They are short (6 to 8 nucleotides) and
degenerate sequences that can promote (enhancers) or
repress (silencers) exon inclusion in the mature mRNA.
Sequence variations in any of these elements can result in
alterations of the pre-mRNA processing step that can also
be associated with human disorders, including hereditary
cancer [14-18].
Identification of the splicing regulatory elements (SRE)
by computational predictions is not accurate because of
the degeneracy of these motifs [11,14,19,20], supporting
the importance of RNA analysis to demonstrate the dele-
teriousness of a particular DNA change. However, it is
often complex to obtain extra blood samples for RNA
extraction from patients carrying a suspicious DNA
change. Splicing functional analysis with hybrid minigenes
is a simple and robust approach to study potential variants
with impact on splicing without the need of collecting
additional blood samples from patients. The genomic
region of interest (exons and their flanking introns) from
control and affected individuals can be cloned into a spli-
cing reporter plasmid such as pSPL3. The construct is
then transiently transfected into eukaryotic cells and the
splicing pattern is analyzed by RT-PCR with specific pri-
mers of plasmid exons. The minigene assay constitutes a
useful approach for identifying splicing anomalies and the
study of their underlying functional mechanisms [21,22].
We previously studied 57 different pre-selected DNA var-
iants from BRCA1 and BRCA2 using a combined
approach: bioinformatics analysis and splicing assays by
lymphocyte RNA RT-PCR and/or hybrid minigenes.
Twenty-eight out of the 57 pre-selected variants displayed
abnormal splicing patterns, suggesting that disruption of
this process is an important disease mechanism [14].
In this study, we have performed a splicing analysis of
BRCA2 variants c.8488-1G > A (acceptor site of exon 20)
and c.9026_9030del (exon23) by lymphocyte RT-PCR
and splicing reporter minigenes of exons 19-20 and 23-
24. Moreover, we have extended this analysis to another
41 candidate splicing DNA variants of these exons
reported in the BIC mutation database. A total of 19 var-
iants induced aberrant splicing and we identified and
quantified up to 12 different aberrant RNA isoforms
from minigenes of exons 19-20 and 23-24.
Materials and methods
Patients, nucleic acid isolation and mutation detection
Breast and/or ovarian cancer patients harboring variants
c.8488-1G > A and c.9026_9030del (nine families) were
selected by the Genetic Counseling Unit (Complejo
Hospitalario de Burgos) [23]. Written, informed consent
was obtained from all patients prior to blood extraction.
This study was approved by the ethics committee of the
Faculty of Medicine, University of Valladolid (Spain).
DNA and RNA were purified from peripheral blood
lymphocytes of patients VA1220 (c.8488-1G > A) and
VA1612 (c.9026_9030del) by using the QIAamp DNA
and RNA blood mini kit (Qiagen, Hilden, Germany),
respectively. RNA purification included a DNAse I treat-
ment step. Mutation detection was performed by capil-
lary heteroduplex analysis [24,25]. Nomenclature of
sequence variations follows the guidelines of the Human
Genome Variation Society (HGVS) [26], and was based
on the BRCA2 cDNA sequence NM_000059.
Splicing prediction programs
To identify potential variants with impact on splicing,
mutant and reference sequences were analyzed with the
following programs: a) NNSPLICE, which evaluates the
strength of splice sites [27], and Human Splicing Finder
(HSF) [28], which includes several matrices to analyze
splice sites and splicing silencers and enhancers (for exam-
ple, MaxEnt, ESEfinder, PESX and so on). In order to
improve the specificity of ESEfinder predictions [29] we
examined the evolutionary conservation of ESE motifs by
aligning the BRCA2 sequences of different organisms with
CLUSTALW2 [30].
Lymphocyte RT-PCR
Lymphocyte RNA from patients carrying variants c.8488-
1G > A (exon 20) and c.9026_9030del (exon 23) was retro-
transcribed with the High Capacity kit (Applied Biosys-
tems, Carlsbad, CA, USA). Amplification of cDNA was
conducted with GoTaq Hot Start DNA polymerase (Pro-
mega, Madison, WI, USA) and flanking exonic primers
forward RTBR2_EX19-FW, 5’AAACTTGGATTCTTT
CCTGAC 3’ (exon 19), and reverse RTBR2_EX23-RV,
5’ATTCTGTATCTCTTTCCTTCTGTT 3’ (exon 23), for
variant c.8488-1G > A (amplicon length: 653 bp), and
RTBR2_EX22-FW, 5’ GTGAAGAGCAGTTAAGAGCCT
3’ (exon 22), and RTBR2_EX26-RV, 5’ CTTGTTTTCTGC
TTCATTGC 3’ (exon 26) for variant c.9026_9030del
(amplicon length: 773 bp). Splicing profiles of patients
Acedo et al. Breast Cancer Research 2012, 14:R87
http://breast-cancer-research.com/content/14/3/R87
Page 2 of 12
were compared with those obtained from RT-PCR experi-
ments of control lymphocytes and non-tumorigenic breast
epithelial cells (MCF10A; ATCC, LGC Standards) [31].
RT-PCR products were run on 1.5% agarose gels and
stained with ethidium bromide. Isoforms induced by var-
iant c.8488-1G > A were sequenced with the Big Dye 3.1
Sequencing Kit (Applied Biosystems) and primers
RTBR2_EX19-FW and RTBR2_EX23-RV.
Construction of minigenes
Wild type (wt) exons 19-20 (intron 18-exon 19-intron 19-
exon 20-intron 20) and 23-24 (intron 22-exon23-intron
23-exon 24-intron 24) of BRCA2 were amplified with
Pfx50 high fidelity polymerase (Invitrogen, Carlsbad, CA,
USA) and primers with a restriction site (underlined) for
either XhoI or BamHI: MGBR2_ex19-20_XhoI-FW, 5’
CACACACTCGAGATAGCATTAAGAACTTGTAGCA
3’, and MGBR2_ex19-20-BamHI-RV, 5’ CACACAG-
GATCCATTACAAATGGCTTAGACCTGA 3’ (Exons
19-20; size: 1164 bp); and MGBR2_ex23-24_XhoI-FW, 5’
CACACACTCGAGAATGCTTTGTTTTTATCAGTTTT
3’, and MGBR2_ex23-24_BamHI-RV: 5’ CACACAG-
GATCCAATTTGCCAACTGGTAGCTC 3’ (exons 23-24;
size: 717 bp).
After digestion with XhoI and BamHI (Fermentas, Vil-
nius, Lithuania), fragments were ligated to the exon trap-
ping vector pSPL3 (Invitrogen, discontinued) to transform
DH5a competent cells (Invitrogen). The new constructs
were sequenced with the Big Dye 3.1 Sequencing Kit
(Applied Biosystems) and primers PSPL3-SEQ-FW (5’
CCTTGGGATGTTGATGAT 3’) and PSPL3-SEQ-RV (5’
TTGCTTCCTTCCACACAG 3’).
Site directed mutagenesis
Mutagenesis was carried out according to the PCR muta-
genesis protocol with Pfu Turbo DNA polymerase (Agi-
lent, Santa Clara, CA, USA) [32]. Wild type (wt)
minigenes of BRCA2 exons 19-20 and 23-24 were used as
templates to generate 41 candidate variants from the BIC
database [see Additional file 1, Table S1]. In addition,
several artificial variants were designed to target putative
regulatory motifs: c.8484A > T and c.8486A > C, c.8512T
> A, c.8518del and two combined BIC variants c.[8609A
> G;8611G > T] and c.[8972G > A; 9006A > T] within
the same construction. Finally, two conserved motifs of
intron 19 were deleted separately and together: c.8487
+31_8487+42del, c.8488-49_8488-44del, and c.[8487
+31_8487+42del; c.8488-49_8488-44del].
Transfection of HeLa cells
Approximately 105 HeLa cells (human cervical carci-
noma) were grown to 90% to 95% confluency in 0.5 mL
of growth medium ((D)MEM, 10% fetal bovine serum,
1% glucose and 1% penicillin/streptomycin) in four-well
plates (Nunc, Roskilde, Denmark). Cells were transfected
with 1 μg of plasmid minigene and 2 μL of lipofecta-
mine 2000 (Invitrogen) following the manufacturer’s
protocol. After 48 hours RNA was purified with
Nucleospin-RNA-II (Macherey-Nagel, Düren, Germany)
that includes on-column rDNAse treatment and quanti-
fied in a Nanodrop 1000 spectrophotometer (Fisher
Scientific, Spain).
RT-PCR of minigenes and quantification of mRNA
isoforms
Retrotranscription was carried out with 200 ng of RNA
and the transcriptor first strand cDNA synthesis kit
(Roche, Sant Cugat del Vallés, Barcelona, Spain). Semi-
quantitative fluorescent RT-PCRs were performed in tri-
plicate in a final volume of 20 μL that contained 2 μL of
cDNA and the flanking primers of constitutive exons of
pSPL3, SD6-PSPL3_RTFW (FAM-5’ TCACCTGGA-
CAACCTCAAAG 3’) and SA2-PSPL3_RTREV (5’ TGAG-
GAGTGAATTGGTCGAA 3’). Samples were denatured at
94°C for five minutes, followed by 26 cycles consisting of
94°C for 20 seconds, 58°C for 20 seconds, and 72°C for 30
seconds, and a final extension step at 72°C for two min-
utes. Sizes of the RT-PCR products were 486 and 488 bp
for minigenes 19-20 and 23-24, respectively. The RT-PCR
products (1 μL of a 1/10 dilution) were mixed with 18 μL
of Hi-Di Formamide (Applied Biosystems) and 0.2 μL of
Genescan 500 Rox Size Standard (Applied Biosystems).
Samples were run on an ABI3130 sequencer using POP7
polymer and analyzed with the Peak Scanner software
(Applied Biosystems). Mean peak areas were used to cal-
culate ratios of the different splicing isoforms generated by
DNA variants from minigenes 19-20 and 23-24.
Sequencing of the minigene RT-PCR products was car-
ried out as described above with primers SD6-
PSPL3_RTFW and SA2-PSPL3_RTREV except for intron
19 retention isoform that was sequenced with a specific
primer in the boundary intron 19-exon 20 (RTBR2_ivs19-
ex20-RV: 5’ TGTCTTCTCCATCCACTGTAAT 3’).
Results and discussion
Variant c.8488-1G > A was detected in a patient who
developed bilateral breast cancer at age 66 and 74 and
ovarian cancer at age 77. This variant affects the essential
nucleotide -1 (G to A) of the acceptor splice site of
BRCA2 exon 20. This variant had not been reported at the
BIC mutation database although it had formerly been
found in a consanguineous Fanconi anemia patient [33].
Analysis with HSF at the intron/exon boundary identified
a weak acceptor splice site that was even weakened by the
change -1 G > A. Lymphocyte RT-PCR of the carrier
patient revealed an upper band with intron 19 retention
(1053 bp) and a transcript with a 12-nucleotide deletion of
exon 20 generated by the use of an alternative cryptic
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acceptor [see Additional file 1, Figure S1]. This variant was
also evaluated by hybrid minigenes of exons 19-20. Spli-
cing assay and fluorescent RT-PCR (Figure 1B and Addi-
tional file 1, Figure S1) revealed three main isoforms:
12-nucleotide deletion of exon 20 (9.7%), intron 19 reten-
tion (16.0%), exon 20 skipping (72.1%), which was not pre-
viously identified in lymphocytes, and other minor
isoforms. The different splicing profiles between both
assays may be due to the different genomic context where
adjacent exons may be involved in the splicing efficiency
of exons 19 and 20 [34]. The most common events of
alternative splicing are exon skipping and alternative splice
site selection whereas intron retention is the less frequent
phenomenon in physiological alternative splicing [35],
indicating that its contribution to the complexity of the
human proteome is low since this event is usually asso-
ciated with the introduction of premature stop codons
[36]. Moreover, intron retention is increased by two-fold
in cancerous cells, suggesting the disruption of essential
repressor genes of tumor progression [36]. Nevertheless,
intron retention rate can be particularly high in some spe-
cific genes such as the Kallikrein gene family of serine pro-
teases, in which six isoforms showed intron III exonization
and were predicted to truncate all the resultant proteins
[37].
Translation of the intron 19 retention and exon 20
skipping isoforms was predicted to result in truncated
proteins (p.Gln2829fsX2 and p.Trp2830LysfsX13,
respectively), whereas the 12-nucleotide deletion pro-
duced an in frame deletion of four amino acids (p.
Trp2830_Lys2833del, W-M-E-K) of the BRCA2 DNA
binding domain. Tryptophan 2830 and glutamic acid
2832 are strictly conserved in vertebrates, (IARC BRCA2
alignment), suggesting their functional relevance [38].
Moreover, one Fanconi anemia patient of subtype D1
(associated with BRCA2 mutations) with a family history
of consanguinity was previously reported to be homozy-
gous for this variant [33]. Altogether these data strongly
support the pathogenicity of c.8488-1G > A.
BRCA2 c.9026_9030del of exon 23 is a deleterious fra-
meshift mutation that would lead to a premature stop
codon (p.Tyr3009SerfsX9). It is one of the most prevalent
mutations in the Spanish population, accounting for 7.6%
of BRCA2 families in Castilla y León (Spain) [39]. We
had already shown that other deletions, such as BRCA2
c.470_474del, can induce splicing defects [14]. HSF ana-
lysis predicted changes in several presumed regulatory
elements (Exon and Intron Identity Elements) [40]. We
performed lymphocyte RT-PCR of one carrier patient
and we found the wt allele and the corresponding 5-
nucleotide deletion transcript derived from the genomic
variant (c.9026_9030del) without any splicing anomaly
(data not shown). This result was confirmed in the mini-
gene of exons 23 and 24 (Figure 1F).
Minigene analysis of BIC variants
We had previously shown that first, more than 20% of
BRCA variants reported at the BIC database can induce
splicing disruptions and, second, the combination of PCR
mutagenesis and splicing reporter plasmids is a straight-
forward and strong approach that allows the analysis of
the splicing effect of any sequence change [14]. We, there-
fore, proceeded to analyze all the reported variants of
exons 19, 20, 23 and 24 from the BIC database (155 differ-
ent DNA changes) with NNSplice and HSF. We chose var-
iants that met one of the following criteria: disruption of
the natural splice site, creation of novel alternative donor
or acceptor sites, alteration of evolutionarily conserved
ESEs, and creation of splicing silencers. A total of 41 var-
iants (26.5%) were preselected and generated by PCR
mutagenesis in the wt minigenes 19-20 and 23-24. Splicing
functional assays were carried out by semiquantitative
fluorescent RT-PCR and the peak areas of the different
isoforms were quantified. Eighteen variants (43.9%) pro-
duced aberrant splicing patterns (Table 1, Figure 1 and
Additional file 1, Figure S2) that affected the natural splice
sites (12 variants: c.8487+1G > A, c.8487+3A > G, c.8488-
2A > G, c.8954-3C > G, c.8954-1_8955delinsAA, c.9117G
> A, c.9117+1G > T, c.9117+1G > A, c.9118-2A > G,
c.9248_9256+7del, c.9256G > T and c.9256+1G > A), spli-
cing enhancers or silencers (four variants: c.8378G > A,
c.8969G > A, c.9006A > T and c.9076C > T) or both of
them simultaneously, splice site and enhancer (c.8486A >
T and c.8487G > A). Interestingly, variant c.8488-2A > G
(Figure 1C) replicated the splicing pattern of c.8488-1G >
A (Figure 1B) although slight differences in the relative
proportions of each isoform were observed [see Additional
file 1, Figure S3]. Variants c.8486A > T and c.8487G > A
of the penultimate and last nucleotides of exon 19, respec-
tively, decreased the canonical donor splice site score of
intron 19 (MaxEnt -480% and -502%, respectively) and
NNSPLICE (0.95®0.87 and 0.95®0.4, respectively) but
also disrupted one putative SF2/ASF enhancer. To ascer-
tain the nature of these splicing anomalies two artificial
variants were designed and generated: c.8484A > T (intact
splice site and SF2 disruption) and c.8486A > C (weak
alteration of splice site: 0.95 ®0.92 and SF2 disruption;
Additional file 1, Table S1). The first one, c.8484A > T,
only revealed the wt isoform whereas c.8486A > C pro-
duced total exon 19 skipping [Additional file 1, Figure S3].
Consequently, only those variants that were predicted to
affect the donor site, even slightly (c.8486A > T, c.8486A >
C and c.8487G > A), altered the splicing process, suggest-
ing that this is the causative mechanism. Actually, the last
and penultimate exonic nucleotides of exons as well as the
intronic positions +1 to +5 and -3 to -1 are also highly
conserved [11] and should be considered potential targets
of variants with impact on splicing [41]. Finally, we also
generated another five artificial variants, c.8512T > A and
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Ex23 51-nt del 
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c.8486A>T Ex19 skipping 
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c.8488-2A>G Ex20 skipping 
Ex20 12-nt del Ivs19 retention R
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K) 
Figure 1 Splicing outcomes of variants of exons 19-20 (A-D) and 23-24 (E-K) of BRCA2. RT-PCRs labelled with FAM (shadowed blue peaks)
of mutant minigenes were run in an ABI3130 sequencer with Genescan ROX 500 (red peaks) as size standard. Aberrant isoforms are indicated
by arrows. RFU: Relative Fluorescence Units. A-D) Chromatograms of the wt minigene and variants of c.8488-1G > A (intron 19), c.8488-2A > G
(intron 19), and c.8486A > T (exon19). E-K) Chromatograms of the wt minigene and variants c.9026_9030del (exon 23), c.8954-1_8955delinsAA
(intron 22-exon23), c.8954-3C > G (intron 22), c.9117+1G > A (intron 23), c.9118-2A > G (intron 23), and c.9256+1G > A (intron 24). wt, wild type.
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Table 1 Bioinformatics analysis and RNA results of variants with impact on splicing of BRCA2 exons 19, 20, 23 and 24.
Mutation
(HGVS)a
Bioinformatics analysisc Splicing outcomed RNA effect
(HGVS)a
Predicted protein effect
(HGVS)a
Exons 19-20b WT Minigene 19-20: N_Sp
(99%)
c.8378G > A
(ex19)
[-] ESE, [+] hnRNP-B N_Sp/Ex19 skipping r.[8378g > a, 8332_8487del] p.[G2793E, Ile2778_Gln2829del]
c.8486A > T (ex19) ↓score donor site/[-] SF2/
ASF
Ex19 skipping r.8332_8487del p.Ile2778_Gln2829del
c.8487G > A
(ex19)
↓score donor site/[-] SF2/
ASF
Ex19 skipping r.8332_8487del p.Ile2778_Gln2829del
c.8487+1G > A
(ivs19)
[-] Donor site disruption. Ex19 skipping r.8332_8487del p.Ile2778_Gln2829del
c.8487+3A > G
(ivs19)
↓score donor site. Ex19 skipping r.8332_8487del p.Ile2778_Gln2829del
c.8488-2A > G
(ivs19)
[-] Acceptor site Intron retention/Ex20_12nt
deletion/Ex20 skipping
r.[8487_8488ins8487+1_8488-1,
8488_8499del, r.8488_8632del]
p.[Gln2829fsX2,
Trp2830_Lys2833del
Trp2830LysfsX13]
c.8488-1G > A
(ivs19)
[-] Acceptor site Intron retention/Ex20_12nt
deletion/Ex20 skipping
r.[8487_8488ins8487+1_8488-1,
8488_8499del, r.8488_8632del]
p.[Gln2829fsX2,
Trp2830_Lys2833del
Trp2830LysfsX13]
Exons 23-24b WT Minigene 23-24: N_Sp
(100%)
c.8954-3C > G
(ivs22)
[+] Acceptor site 2-nt
upstream
Ex23_2-nt insertion r.8954-2_8954-1ins p.Val2985GlufsX4
c.8954-
1_8955delinsAA
(ivs22-ex23)
Disruption acceptor site Ex23_51-nt deletion/Ex23
skipping/Ex23+24 skipping
r.[8954_9004del, 8954_9117del,
8954_9256del]
p.[Val2985_Thr3001del,
Val2985GlyfsX3, p.
Val2985_Thr3085del]
c.8969G > A
(ex23)
[+] hnRNPA1; [+] hnRNP-B N_Sp/Ex23_51-nt del r.[8969g > a, 8954_9004del] p.[W2990X, Val2985_Thr3001del]
c.9006A > T (ex23) [-] SRp40; ↑score cryptic
site
N_Sp/Ex23_51-nt del r.[9006a > u, 8954_9004del] p.[E3002D, Val2985_Thr3001del]
c.9076C > T (ex23) [+] ESS N_Sp/Ex23 skipping/Ex23+24
skipping
r.[9076c > u, 8954_9117del,
8954_9256del]
p.[Q3026X, Val2985GlyfsX3,
Val2985_Thr3085del]
c.9117G > A
(ex23)
[-] Donor site Ex23 skipping/Ex23_51-nt
del/Ex23+24 skipping
r.[8954_9117del, 8954_9004del,
8954_9256del]
p.[Val2985GlyfsX3,
Val2985_Thr3001del,
Val2985_Thr3085del]
c.9117+1G > T
(ivs23)
[-] Donor site Ex23 skipping r.8954_9117del p.Val2985GlyfsX3
c.9117+1G > A
(ivs23)
[-] Donor site Ex23 skipping r.8954_9117del p.Val2985GlyfsX3
c.9118-2A > G
(ivs23)
[-] Acceptor site. Novel
acceptor 7-nt downstream
Ex24_7-nt del/Ex24_24-nt
del/Ex23+24 skipping
r.[9118_9124del, 9118_9141del,
8954_9256del]
p.[Val3040MetfsX20,
Val3040_Gln3047del,
Val2985_Thr3085del]
c.9248_9256+7del
(ex24-ivs24)
[-] Donor site Ex24 skipping/Ex24_43-nt
del/Ex23+24 skipping
r.[9118_9256del, 9214_9256del,
8954_9256del]
p.[Val3040AspfsX18,
Val3072AspfsX18,
Val2985_Thr3085del
c.9256G > T (ex24) [-] Donor site Ex24 skipping/Ex23+24
skipping/Ex24_43-nt del/
N_Sp
r.[9118_9256del, 8954_9256del,
9214_9256del,9256g > u]
p.[Val3040AspfsX18,
Val2985_Thr3085del,
Val3072AspfsX18, G3086X]
c.9256+1G > A
(ivs24)
[-] Donor site Ex24 skipping/Ex23+24
skipping/Ex24_43-nt del
r.[9118_9256del, 8954_9256del,
9214_9256del]
p.[Val3040AspfsX18,
Val2985_Thr3085del,
Val3072AspfsX18]
aNomenclature of variants at DNA, RNA and protein levels follows the guidelines of the Human Genome Variation Society. bIntronic (ivs) or/and exonic (ex)
location of each variant are indicated between brackets. cSummary of bioinformatics results with NNSPLICE and Human Splicing Finder. [-], disruption; [+],
creation. ESE, Exonic Splicing Enhancer; ESS, Exonic Splicing Silencer; SF2/ASF and SRp40 are SR proteins that bind ESE/enhancer motifs; hnRNP proteins bind
ESS/silencer motifs. dMajor isoforms are described. EX, exon; nt, nucleotide; del, deletion. Wild type minigene of exons 19 and 20 produced a minimal amount
(1%) of exon 19 and exons 19+20 skipping. Variants with a relevant fraction of the wild type isoform are italicized (N_Sp: Normal Splicing). The relative
proportions of each isoform are shown in Additional file 1, Figure S3.
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c.8518del (disruption of conserved SC35 and SRp55 ESEs),
and three single and combined deletions of two conserved
intron 19 motifs (c.8487+31_8487+42del, c.8488-49_8488-
44del and c.[8487+31_8487+42del; c.8488-49_8488-44del];
Additional file 1, Table S1) that were genetically engi-
neered in the respective minigenes but neither of them
showed patent splicing anomalies.
Aberrant RNA isoforms and predicted effect on protein
A total of 14 different RNA isoforms, including the
canonical transcripts, were detected in the minigene
experiments of exons 19-20 (five isoforms) and 23-24
(nine isoforms; Additional file 1, Figure S2). The 12
aberrant isoforms (Figures 2 and 3) were caused by four
different events including exon skipping (four isoforms:
exons 19, 20, 23 and 24 skipping), double exon skipping
(exons 23+24), intron 19 retention and use of alternative
cryptic acceptor or donor splice sites (exon 20del12,
exon 23ins2, exon 23del51, exon 24del7, exon 24del24
and exon 24del43). Moreover, most variants (12/19;
Table 1) produced two or more distinct RNA isoforms.
Likewise, the high resolution of the fluorescent RT-PCR
technique in splicing reporter assays should be high-
lighted as it allowed accurate detection of isoforms that
differed in size by as little as two (exon 23ins2) or seven
nucleotides (exon 24del7) (Figure 3), which otherwise
could be masked by the wt isoform in agarose gel elec-
trophoresis [42]. Furthermore, its high resolution is cap-
able of detecting minor transcripts (less than 5% of total
mRNA isoforms; Additional file 1, Figure S3) that could
not be visualized in agarose gels. Finally, the minigene
assay is a single-allele assay that allows a precise quanti-
fication of the different RNA isoforms without the inter-
ference of the normal allele as in lymphocyte RT-PCR.
However, the Nonsense-Mediated mRNA Decay (NMD)
mechanism selectively degrades mRNAs harboring pre-
mature termination codons (PTC) that can impair the
relative proportions of each isoform. In fact, 13 out of
14 transcripts, including the wt ones (Figures 2 and 3),
do not keep the ORF of exon 1 of pSPL3 and are, there-
fore, susceptible to undergo NMD unless this process is
inhibited in cell culture [43], so special care should be
taken in interpreting these results.
With regard to the putative pathogenicity of variants
with an effect on splicing, two basic criteria are consid-
ered biological indicators [16-18]: first, total or almost
total splicing disruption (absence of the canonical tran-
script); and second, the predicted effects of aberrant
Ex?19?skipping Ex?20?skipping WT
Size?(bp)
320 360 400 440 480 780 820
A)
Ex?19 Ex?20Ex?V1 Ex?V2 WT
Intron?19?
retention
Ex?20del12
RF
U
B)
Ex?19 Ex?20Ex?V1 Ex?V2
Ex?19 Ex?20Ex?V1 Ex?V2
ivs19Ex?19 Ex?20Ex?V1 Ex?V2
Exon?20??skipping
Intron?19?retention
Exon?19??skipping
Ex?19 Ex?20Ex?V1 Ex?V2
AG
Exon?20del12
Figure 2 Splicing isoforms generated by DNA variants of exons 19 and 20. A) Fluorescent RT-PCRs (blue peaks) of mutant minigenes were
run in an ABI3130 DNA sequencer with Genescan ROX 500 (red peaks) as size standard. Chromatograms of different variants were overlaid to
generate this picture. B) Diagrams of the splicing outcomes caused by variants of exons 19 and 20.
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transcripts on protein translation, such as introduction of
frameshifts and premature stop codons or loss of essen-
tial domains of BRCA2 (Table 1). Thirteen BIC variants
of the splice sites (c.8486A > T, c.8487G > A, c.8487+1G
> A, c.8487+3A > G, c.8488-2A > G, c.8954-3C > G,
c.8954-1_8955delinsAA, c.9117G > A, c.9117+1G > T,
c.9117+1G > A, c.9118-2A > G, c.9248_9256+7del and
c.9256+1G > A) induced major splicing defects that con-
sisted of exon skipping, double exon skipping, insertion
of nucleotides and partial deletions of exons due to the
use of cryptic acceptor or donor sites. Translation of the
anomalous transcripts was predicted to result in protein
truncation (exon 20 skipping, intron 19 retention, exon
23 skipping, exon 24 skipping, exon 23ins2, exon 24del7
and exon 24del43) or in-frame deletions (ex19 skipping,
exon 20del12, exon 23del51, exons 23+24 skipping, exon
24del24) of conserved amino acids of the essential
BRCA2 DNA binding domain (Table 1) which spans
amino acids 2500 to 3098, suggesting that these variants
might have a role in the disease. On the other hand, var-
iant c.9256G > T of exon 24 produced a significant frac-
tion of the canonical transcript (42.3%; Additional file 1,
Figure S3). However, the canonical transcript contains
the nonsense change r.9256g > u, thus supporting a
Ex?23?ins2Ex?23?skipping Ex?24?skipping Ex?23?del51
Ex?24del7
WT
200 360 400 440 480
Size?(bp)A)
23 24V1 V2 WT
Ex?23+24
skipping Ex?24del43
RF
U
Ex?24del24
B)
23 24V1 V2
23 24V1 V2
23 24V1 V2
Exon?23??skipping
Exon?24??skipping
Exons?23+24??skipping
23 24V1 Ex?V2AG
23 24V1 V2AG
23 24V1 V2AG Exon?23ins2
Exon?23del51
Exon?24del7
23 24V1 V2AG
23 24V1 V2
Exon?24del24
Exon?24del43GT
Figure 3 Splicing isoforms generated by DNA variants of exons 23 and 24. A) Fluorescent RT-PCRs (blue peaks) of mutant minigenes were
run in an ABI3130 DNA sequencer with Genescan ROX 500 (red peaks) as size standard. Chromatograms of different variants were overlaid to
generate this picture. B) Diagrams of the splicing outcomes caused by variants of exons 23 and 24.
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double deleterious mechanism: protein truncation (p.
G3086X) and splicing disruption (three aberrant iso-
forms; Table 1). Other variants, such as BRCA1 c.5123C
> A and BRCA2 c.8168A > G (both missense changes),
had already been shown to alter protein function and
pre-mRNA processing [4,5,14,44].
In contrast, the four SRE variants (ESE disruption and/
or ESS creation; Table 1) had low to moderate effects on
splicing since aberrant isoforms accounted for 8%
(c.8969G > A) to 22% (c.9006A > T) of total transcripts.
Up to now we have detected 16 SRE variants (two of them
artificial variants) [14] of which five are placed in BRCA2
exon 5 suggesting that regulation of some exons strongly
depends on supplementary cis-regulatory elements such as
ESE or ESS. Thus, it is expected that each exon is regu-
lated by different mechanisms that can only be determined
experimentally. Another two putative silencer variants
(c.9148C > T and c.9227G > T) showed minor splicing
defects (< 2% of transcripts; data not shown) that were not
considered relevant. Interestingly, the combination of two
putative ESE variants, c.8972G > A (SRp55) and c.9006A >
T (SRp40), in the same exon 23-24 minigene induced a
greater splicing defect than each variant alone. In addition,
variant c.9006A > T also strengthened the cryptic acceptor
site 51 nucleotides downstream of the canonical one that
is used in one aberrant isoform (exon 23del51; Figure 3).
In single assays, c.8972G > A had no effect on splicing as
previously reported [45] whereas c.9006A > T produced
the canonical transcript (68.8%), exon 23del51 (19.7%),
exon 23 skipping (9.2%) and exons 23+24 skipping (2.3%).
Surprisingly, we found that the combination of both var-
iants increased the fraction of the 51-nucleotide deletion
isoform from 19.7% to 39.9% whereas the other anomalous
isoforms decreased [See Additional file 1, Figures S3 and
S4]. Furthermore, acceptor and donor sites of exon 23 are
weak, suggesting that supplementary control elements are
required for correct exon 23 recognition [46]. Altogether
these data suggest that exon 23 recognition depends, at
least in part, on the splicing factors SRp55 and SRp40 that
might act cooperatively although this issue should be con-
firmed by RNA binding assays. Conversely, other SRE var-
iants were previously proven to trigger complete splicing
defects, such as BRCA1 c.5080G > T and BRCA2 c.93G >
T, c.145G > T or c.470_474del [14,47].
Pathogenicity of variants with incomplete splicing out-
comes is uncertain but they might constitute low-moder-
ate penetrance alleles of breast/ovarian cancer as it occurs
in CFTR-related disorders [48]. Thus, the penetrance and
severity of this group of diseases are correlated with an
abnormal number of UG and U repeats located in the
acceptor site of exon 9 of the CFTR gene, which increase
the exon 9 skipping rate. Consequently, genetic variation
can affect splicing efficiency that can modify the severity
of the disease phenotype or be linked with disease suscept-
ibility [10]. In any case, additional epidemiological studies
should be conducted to estimate accurately the breast/
ovarian cancer risks of DNA variants with total and partial
defective splicing outcomes.
Conclusions
Taking all these results together, 12.2% of all the var-
iants (19/155) of BRCA2 exons 19, 20, 23 and 24 are
associated with splicing defects. They comprise three
nonsense, three missense, two synonymous and 11
splice site variants (including two deletions), indicating
that any DNA change can disrupt pre-mRNA proces-
sing. Furthermore, in this and previous reports [14], we
have analyzed in depth 14 exons of BRCA1 and BRCA2
(541 different BIC DNA variants) and detected 45 nat-
ural variants with an impact on splicing of which 21
altered splice sites, 14 modified SREs (enhancer disrup-
tion and/or silencer creation), eight created alternative
sites and two affected the polypyrimidine tract. How-
ever, taking into account all the critical positions of the
splice sites (intronic -3 to -1 and +1 to +5, and the con-
served exonic nucleotides) of those 14 exons, the num-
ber of variants with impact on splicing would therefore
increase to 85 (15.7% of all reported BIC variants) that
would account for 33.9% of all presumed deleterious
mutations (113 frameshift, 53 nonsense and 85 splicing
variants), more than two-fold higher than the classical
estimate [13].
Computational predictions of variants at the splice
sites were precise by the three algorithms used in this
work, but only HSF was able to identify all the cryptic
alternative sites of exons 20, 23 and 24 (Figures 2 and
3). In contrast, bioinformatics evaluations of enhancer
inactivation or silencer creation were not so accurate
and had a high false-positive rate. A complete knowl-
edge of the splicing code will enhance sensitivity of
these bioinformatics predictions [46]. However, the con-
struction of one single prediction model seems to be an
arduous task that will require comprehensive experi-
mental validations [19].
Direct analysis of splicing anomalies in patient RNA
should be the method of choice to identify variants with
an effect on splicing but this approach presents two prin-
cipal limitations. First, the patient sample might not be
available and, second, leukocytes are the main source of
RNA, so caution should be taken when interpreting these
results since differential tissue-specific alternative splicing
events could mask the real splicing outcome of a DNA
variant [21,34]. In this context, splicing reporter mini-
genes are valuable tools to corroborate bioinformatics
data. This and previous reports have also shown its
importance for the identification of variants with an
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effect on splicing without the need of patient RNA sam-
ples that are usually difficult to obtain [14,18].
As a general rule, splicing profiles of patient and mini-
gene RNA are very similar [14,19,49]. However, we have
observed discrepancies between splicing anomalies of
patient RNA and minigene assays, such as variants
c.8488-1G > A (this work) and c.212+1G > A of BRCA1
exon 5 [14]. The clinical relevance of c.8488-1G > A has
been discussed above and that of c.212+1G > A is
strongly supported by family, bioinformatics (donor site
disruption) and functional data as well as by the fact
that other variants of the donor site of exon5/intron 5
(c.211A > G and c.212+3A > G) were definitely classi-
fied as deleterious mutations by several approaches
[19,50,51]. Therefore, it seems that the observed differ-
ences may probably be due to a technical issue of mini-
gene constructs with particular exons where the lack of
the natural genomic environment without its neighbor-
ing exons can be responsible for the different results
obtained. Moreover, it was previously reported that a
minigene containing only exon 37 of the NF1 gene with
the pathogenic variant 6792C > G principally induced
exon 37 skipping. Conversely, a minigene with exons 31
to 38 with the same variant replicated almost exactly
the splicing pattern of patient lymphoblasts (canonical
transcript, exon 37 skipping and exons 36+37 skipping)
[34]. Consequently, larger minigene constructions with
more exons should be carried out in order to mimic the
natural genomic background. The minigene system is a
straightforward and robust assay that helps to classify
DNA variants of unknown clinical significance under
the splicing viewpoint, although these tests require
further validation. As more data are collected, it will
provide a more accurate risk estimation of breast and
ovarian cancer associated with splicing alterations.
Finally, analysis of minigene RT-PCR products in a
DNA sequencer provides higher resolution than agarose
electrophoresis [42,52], since we have shown that a pre-
cise identification of minor or rare transcripts and quan-
tification of all the isoforms generated by a specific
DNA change is possible (Figures 2 and 3).
In conclusion, an important fraction of DNA variants
are associated with splicing aberrations that should be
considered as a primary mechanism of gene inactivation
to be investigated in unclassified DNA variants. These
studies provide insights into the basic regulatory
mechanisms of this step of eukaryotic gene expression
contributing to a better knowledge of the rules for exon
definition. Hence, splicing functional assays supply
essential information to distinguish between neutral var-
iants and variants with an impact on splicing and should
be incorporated in genotype screenings of human her-
editary diseases.
Additional material
Additional file 1: Bioinformatics and RNA analyses of candidate
DNA variants. Bioinformatics analysis of putative splicing variants of
exons 19, 20, 23 and 24 of BRCA2 (Table S1). Splicing outcomes of DNA
variant c.8488-1G > A (Figure S1). Sequence chromatograms of the main
splicing outcomes of the minigenes 19-20 and 23-24 of BRCA2 (Figure
S2). Quantification of RNA isoforms induced by variants of minigenes of
exons 19-20 and 23-24 (Figure S3). Cumulative effect of ESE mutations
from BRCA2 exon 23 on splicing (Figure S4).
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